4//SEC Filing
Margrave David R. 4
Accession 0001213900-21-056108
CIK 0001763950other
Filed
Nov 1, 8:00 PM ET
Accepted
Nov 2, 4:05 PM ET
Size
5.4 KB
Accession
0001213900-21-056108
Insider Transaction Report
Form 4
Margrave David R.
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2021-10-29+26,100→ 26,100 totalExercise: $10.21Exp: 2031-10-29→ Common Stock (26,100 underlying)
Footnotes (1)
- [F1]The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 36-month period commencing upon November 29, 2021.
Documents
Issuer
Lantern Pharma Inc.
CIK 0001763950
Entity typeother
Related Parties
1- filerCIK 0001813162
Filing Metadata
- Form type
- 4
- Filed
- Nov 1, 8:00 PM ET
- Accepted
- Nov 2, 4:05 PM ET
- Size
- 5.4 KB